INAB News & Events

IN8bio announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 studies at the 2026 American Society of Clinical Oncology, or ASCO, annual meeting. Among patients who received up to six repeat doses of genetically modified gamma delta T cells, median progression-free survival reached 13 months, nearly double the 6.6 months observed in patients receiving standard-of-care alone. mOS has not yet been reached in repeat-dose patients and currently exceeds 19.5 months, compared to a final mOS of 13.2 months for patients receiving only SOC. Approximately 43% of repeat-dose patients remained alive at 24 months versus only 20% of SOC patients. Data are as of the May 15 data cutoff. The studies demonstrated that intracranially delivered DeltEx DRI was generally well tolerated, with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity events reported. Additional translational analyses integrating histopathology with artificial intelligence technology demonstrated that DeltEx DRI treatment drove a cold-to-hot tumor microenvironment shift, with broad T cell infiltration and reduction in immunosuppressive granulocytes not observed in SOC patients. Repeat DeltEx DRI dosing resulting in higher total doses also increased cumulative T cell and CD4+ levels that correlated significantly with overall survival, linking sustained immune reconstitution to improved outcomes in a dose-dependent manner. Taken together these data point to a T cell-mediated local mechanism with systemic reach.

IN8bio announced the promotion of Kate Rochlin, Ph.D., to President and COO, effective immediately. Dr. Rochlin has served as IN8bio's COO since December 2021, following her tenure as Vice President and Associate Vice President of Operations and Innovation beginning in August 2020. In her expanded role, she will continue to oversee company operations as IN8bio advances its clinical and preclinical pipeline and prepares for its next phase of growth.

IN8bio files to sell 14.38M shares of common stock for holders

IN8bio reported updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials in newly diagnosed glioblastoma. The prior results were presented at the 2025 Society for Neuro-Oncology Annual Meeting. The data continue to demonstrate meaningful and durable improvements in progression-free survival when compared with both historical standard-of-care Stupp protocol data and concurrently enrolled SOC treated patients. Patients in both the Phase 1 and 2 who received repeated doses of the Company's investigational therapy, DeltEx Drug-Resistant Immunotherapy gamma-delta T cells, experienced substantial improvements in both median progression-free and median overall survival across multiple clinical centers. This data is put into greater context compared to contemporaneously enrolled patients treated only with SOC at the same clinical trial sites, forming a concurrently treated control cohort: Median progression-free survival: DeltEx DRI 13.0 months vs. 6.6 months with SOC. Median overall survival: DeltEx DRI, not yet reached, currently 17.2+ months and rising, compared with 13.2 months for SOC. Durability: DeltEx DRI, eight of fourteen patients remained progression-free longer than their expected overall survival based on age and MGMT status, compared with just a single patient in the control group. Long-term benefit: Several DeltEx DRI treated patients remain progression-free beyond two years without experiencing any significant DRI related SAEs or DLTs. For the first time, IN8bio presented data from a control group of patients that were contemporaneously enrolled and treated only with the SOC protocols at the same clinical centers with the same treating physicians as the DeltEx DRI cohorts. The SOC control patients performed in-line with expectations based on historical GBM mPFS of 6.9 months, despite a greater number of patients receiving gross total resections. This demonstrates both the aggressive nature of GBM, even with SOC treatment, and the significant need for new treatment options. The funds received from IN8bio's recent financing announced late in 2025 will support further discussions with the FDA on potential clinical pathways, including any potential for accelerated approval. Across both Phase 1, INB-200, and Phase 2, INB-400, trials at multiple centers, DeltEx DRI gammadelta T cells continued to demonstrate a well-tolerated safety profile, with: No DLTs; No cytokine release syndrome; No immune effector cell-associated neurotoxicity; No unexpected infections or SAEs.